Animal and Laboratory Core
动物和实验室核心
基本信息
- 批准号:8492624
- 负责人:
- 金额:$ 79.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-02-07 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdoptedAnimal ModelAnimalsAntigensAutologousB-LymphocytesBiological ModelsBloodBlood specimenBone MarrowCD34 geneCell physiologyCellsControl GroupsDoseEducationEmergency SituationEnsureEventExposure toFibrous capsule of kidneyGenerationsHIVHIV InfectionsHarvestHematopoieticHematopoietic stem cellsHeterosexualsHumanHuman ResourcesImmuneImmune responseImmunodeficient MouseImplantInfectionInstructionInterventionIntravenousInvestigationLaboratory AnimalsLiverMature T-LymphocyteMeasuresMethodsModelingMonitorMusNamesOperative Surgical ProceduresOsteomyelitisPlasmaPositioning AttributeProceduresProtocols documentationResearch PersonnelRiskSafetySamplingScientistStem cellsT-LymphocyteThymic TissueThymus GlandTissue SampleTissuesTransplantationVaccinatedVaccinationVaccinesVaginaViralViral Load resultVirusWorkbonedesignexperiencefetalimplantationimprovedin vivomouse modelnanoparticlenovelpreventprogramsreconstitutionresearch studytransmission processvaginal transmissionvector
项目摘要
Core B, the Animal and Laboratory Core, will provide both the humanized mice, and the HIV viral stocks
to infect them with, for all experiments proposed in this application. Core B will generate BLT (bone marrowliver-
thymus) humanized mice, which provide one of the recently improved humanized mouse models of HIV
infection. BLT mice can be infected with HIV by vaginal transmission, and are capable of producing
functional anti-HIV human immune responses. BLT mice are generated by the surgical implantation of
human fetal thymic and liver tissue under the renal capsules of immunodeficient mice, concurrently with the
intravenous transfer of autologous human hematopoietic stem cells. This protocol allows the human T cells
that mature in these mice to be educated by autologous human thymic tissue rather than by the xenogenic
mouse thymus. This autologous thymic education appears to result in the much improved T cell function,
and consequently much improved human B cell function, that we and others have observed in BLT mice.
Core B has already well-established capacity to provide Program investigators with the numbers of wellreconstituted
BLT mice that they propose to study in this HIVRAD application.
Core B will also perform the vaccinations and/or infections of BLT mice with HIV, and the subsequent
harvesting of blood and tissues from these vaccinated and/or HIV-infected mice. Core B personnel have
extensive experience in performing HIV studies in BLT mice with collaborating investigators. A strong safety
plan is in place to minimize the risk of exposure to Core B personnel performing HIV infections and analyses
of HIV-infected BLT mice, and emergency procedures are in place in case any exposure does occur. Core B
will also work to improve the BLT model of HIV infection, by developing a low-dose repeated mucosal
challenge model. Repetitive challenges will enable the mice to be infected with HIV doses that better
represent those encountered in human heterosexual exposure.
Core B will also provide virological support to all Program investigators. Core B will generate and titer the
stocks of HIV used to infect BLT mice, and measure plasma viral loads in HIV-infected mice by qRT-PCR,
using well-established Core B protocols. Core B has in place the demonstrated capacity to provide the
multiple Clade B, A and C HIV strains that the experiments of this HIVRAD application will require.
Core B thus is well-positioned to support all of the animal and virological requirements of the
investigations proposed in this HIVRAD program.
核心B,即动物和实验室核心,将提供人源化小鼠和HIV病毒储备
来感染它们,用于本申请中提出的所有实验。核心B将产生BLT(骨髓肝-
胸腺)人源化小鼠,其提供了最近改进的HIV人源化小鼠模型之一
感染BLT小鼠可以通过阴道传播感染HIV,并且能够产生
功能性抗HIV人类免疫应答。BLT小鼠通过手术植入
免疫缺陷小鼠肾包膜下的人胎胸腺和肝组织,同时
自体造血干细胞的静脉内移植。该方案允许人类T细胞
在这些小鼠中成熟,通过自体人类胸腺组织而不是异种胸腺组织进行训练,
小鼠胸腺这种自体胸腺训练似乎导致T细胞功能大大改善,
因此大大改善了人类B细胞的功能,这是我们和其他人在BLT小鼠中观察到的。
核心B已经具备了向项目调查人员提供大量经过良好重组的
BLT小鼠,他们建议在这个HIVRAD应用研究。
核心B还将进行BLT小鼠的疫苗接种和/或HIV感染,以及随后的免疫接种。
从这些接种疫苗的和/或HIV感染的小鼠收获血液和组织。核心B人员有
与合作研究者在BLT小鼠中进行HIV研究的丰富经验。强有力的安全
已制定计划,以最大限度地降低执行HIV感染和分析的核心B人员的暴露风险
感染艾滋病毒的BLT小鼠,并采取紧急程序,以防任何接触发生。核心B
还将致力于改善艾滋病毒感染的BLT模型,通过开发低剂量的重复粘膜
挑战模式重复的挑战将使小鼠感染艾滋病毒的剂量更好,
代表人类异性接触中遇到的那些。
核心B还将为所有项目研究者提供病毒学支持。核心B将产生并滴度
用于感染BLT小鼠的HIV原液,并通过qRT-PCR测量HIV感染小鼠中的血浆病毒载量,
使用完善的核心B协议。核心B已证明有能力提供
该HIVRAD应用的实验将需要的多个进化枝B、A和C HIV毒株。
因此,核心B处于良好的位置,以支持本发明的所有动物和病毒学要求。
在这个艾滋病防治计划中提出的调查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TODD M ALLEN其他文献
TODD M ALLEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TODD M ALLEN', 18)}}的其他基金
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
开发同种异体 CAR T 细胞疗法以功能性治愈 HIV 感染
- 批准号:
10480991 - 财政年份:2022
- 资助金额:
$ 79.1万 - 项目类别:
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
开发同种异体 CAR T 细胞疗法以功能性治愈 HIV 感染
- 批准号:
10581704 - 财政年份:2022
- 资助金额:
$ 79.1万 - 项目类别:
Next-Generation Sequencing Center for GHOSTing Hepatitis C Virus: Transforming Community Based Molecular Surveillance and Outbreak Investigation
丙型肝炎病毒重影的下一代测序中心:改变基于社区的分子监测和疫情调查
- 批准号:
10241239 - 财政年份:2017
- 资助金额:
$ 79.1万 - 项目类别:
Leveraging Genetic Engineering Towards a Functional Cure of HIV Infection
利用基因工程实现艾滋病毒感染的功能性治愈
- 批准号:
8897540 - 财政年份:2015
- 资助金额:
$ 79.1万 - 项目类别:
Optimizing Human B and T Cell Vaccines Against HIV Using Humanized BLT Mice
使用人源化 BLT 小鼠优化针对 HIV 的人类 B 和 T 细胞疫苗
- 批准号:
8994707 - 财政年份:2013
- 资助金额:
$ 79.1万 - 项目类别:
Optimizing CD8+ T Cell Vaccine Responses Against HIV
优化 CD8 T 细胞疫苗对 HIV 的反应
- 批准号:
8492547 - 财政年份:2013
- 资助金额:
$ 79.1万 - 项目类别:
Optimizing Human B and T Cell Vaccines Against HIV Using Humanized BLT Mice
使用人源化 BLT 小鼠优化针对 HIV 的人类 B 和 T 细胞疫苗
- 批准号:
8487593 - 财政年份:2013
- 资助金额:
$ 79.1万 - 项目类别:
Optimizing Human B and T Cell Vaccines Against HIV Using Humanized BLT Mice
使用人源化 BLT 小鼠优化针对 HIV 的人类 B 和 T 细胞疫苗
- 批准号:
8788494 - 财政年份:2013
- 资助金额:
$ 79.1万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 79.1万 - 项目类别: